- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
- Major Depressive Disorder
- Women’s Mental Health
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.